Aviragen therapeutics inc share price

Jan 24, 2018 · Digirad has a track record of value destruction: Since its current CEO was appointed on September 1, 2014, Digirad’s share price has declined from $3.61 per share to its current price of $2.65 AVIR: Aviragen Therapeutics, Inc. Stock

Vaxart, Inc Common Stock (VXRT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. VXRT Stock Price | Vaxart Inc. Stock Quote ... - MarketWatch Shares of Vaxart Inc. rocketed 54% on heavy volume in afternoon trading, putting them on track for the first close above the $1 mark in nearly 10 months, after the biotechnology company said it Aviragen Therapeutics, Inc : The latest share price ... *A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: Obtains access to the information in a personal capacity; - AVIR - Stock Price Today - Zacks Investment Research View %COMPANY_NAME% AVIR investment & stock information. Get the latest %COMPANY_NAME% AVIR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. - AVIR - Stock Price Today …

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally.

Latest stock price today and the US's most active stock market forums. Vaxart (VXRT) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. Vaxart, Inc Common Stock (VXRT) Stock Quotes | Nasdaq Vaxart, Inc Common Stock (VXRT) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. VXRT Stock Price | Vaxart Inc. Stock Quote ... - MarketWatch Shares of Vaxart Inc. rocketed 54% on heavy volume in afternoon trading, putting them on track for the first close above the $1 mark in nearly 10 months, after the biotechnology company said it Aviragen Therapeutics, Inc : The latest share price ... *A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: Obtains access to the information in a personal capacity;

CARA Therapeutics, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes opioid-based …

Jan 24, 2018 · Digirad has a track record of value destruction: Since its current CEO was appointed on September 1, 2014, Digirad’s share price has declined from $3.61 per share to its current price of $2.65 AVIR: Aviragen Therapeutics, Inc. Stock Jul 06, 2018 · Real Investment Advice is powered by RIA Advisors, an investment advisory firm located in Houston, Texas with more than $800 million under management. VAXART, INC - Stock Price History | VXRT | MacroTrends The VAXART, INC 52-week high stock price is 3.50, which is 102.3% above the current share price. The VAXART, INC 52-week low stock price is 0.25 , which is 85.5% below the current share price. The average VAXART, INC stock price for the last 52 weeks is 0.76 .

Oct 25, 2019 · Register now to watch these stocks streaming on the ADVFN Monitor. Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Vaxart Inc, formerly known as Aviragen Therapeutics Inc is a bio-pharmaceutical company. It is engaged in developing direct-acting antivirals to treat infections that  Aviragen Therapeutics, together with its wholly owned subsidiaries is a biopharmaceutical company focused on the discovery and development of direct- acting  The latest Plus Therapeutics Inc USD0.001 share price. View recent trades and share price information for Plus Therapeutics Inc USD0.001. Stock analysis for Spark Therapeutics Inc (ONCE) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 2/14/2018. In connection with the merger, Aviragen Therapeutics, Inc. changed its name to Vaxart, Inc. and effected a 1-for-11 reverse split of its common stock. View the latest Proteostasis Therapeutics Inc. (PTI) stock price, news, historical charts, analyst ratings and financial information from WSJ. Aviragen (formerly Biota Pharmaceuticals Inc. ) began a double-blind, its acquisition of Anaconda for $8 million in cash and 3.5 million Biota shares, valued at 

In connection with the merger, Aviragen Therapeutics, Inc. changed its name to Vaxart, Inc. and effected a 1-for-11 reverse split of its common stock. The combined company will commence trading on

Aviragen Therapeutics Inc (NASDAQ:AVIR) Shares Drop on ...

Hepatitis C Virus Envelope Protein E2 Market 2019 Various ... Jan 10, 2020 · Press Release Hepatitis C Virus Envelope Protein E2 Market 2019 Various Manufacturing Industries: Aviragen Therapeutics Inc, Integrated BioTherapeutics Inc Aviragen Therapeutics Inc (AVIR) Announces Definitive ... Oct 30, 2017 · Aviragen Therapeutics Inc (NASDAQ:AVIR) and Vaxart announced the signing of a definitive merger agreement, which will result in a combined company, Vaxart, Inc., focused on developing orally VXRT Stock Price & Charts | Vaxart Aug 09, 2019 · Description: Vaxart Inc is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. AVIR Stock Quote - Stock Price Today